Phenotyping of human IPSC-derived neurons : patient-driven research /

"Phenotyping of Human iPSC-derived Neurons: Patient-Driven Research examines the steps in a preclinical pipeline that utilizes iPSC-derived neuronal technology to better understand neurological disorders and identify novel therapeutics, also providing considerations and best practices. By prese...

Full description

Bibliographic Details
Corporate Author: ScienceDirect (Online service)
Format: eBook
Language:English
Published: London ; San Diego, CA : Academic Press, an imprint of Elsevier, [2023]
Subjects:
Online Access:Connect to the full text of this electronic book
Table of Contents:
  • Front Cover
  • PHENOTYPING OF HUMAN IPSC-DERIVED NEURONS
  • PHENOTYPING OF HUMAN IPSC-DERIVED NEURONS: PATIENT-DRIVEN RESEARCH
  • Copyright
  • Dedication
  • Contents
  • Contributors
  • I
  • Best practices and considerations when designing a new project
  • 1
  • iPSC culture: best practices from sample procurement to reprogramming and differentiation
  • Facility setup
  • Tissue culture room design
  • Tissue culture equipment
  • Primary sample collection
  • Somatic cells
  • Quality control of somatic cells
  • Reprogramming
  • Pros and cons of each method
  • Episomal vector transfection
  • Sendai virus transduction
  • mRNA reprogramming method
  • iPSC line characterization
  • Sterility
  • Pluripotency
  • Transgene elimination
  • Identity
  • Genetic stability
  • Best practices prior to differentiation
  • Cell banking
  • Culturing conditions
  • Differentiation
  • Experimental design
  • Cell line selection
  • Differentiation protocol selection
  • Best practices during differentiation
  • References
  • 2
  • Phenotypic assay development with iPSC-derived neurons: technical considerations from plating to analysis
  • Introduction
  • Establishing optimal conditions for phenotyping iPSC-derived neurons
  • Differentiation protocol considerations
  • Coating substrates
  • High content imaging (HCI)
  • Functional analysis
  • Multi-electrode array (MEA) recording
  • Calcium imaging
  • Patch clamping
  • Live imaging
  • Fluorescent microplate assays
  • Assay development for screening
  • Conclusion
  • References
  • 3
  • Derivation of cortical interneurons from human pluripotent stem cells to model neurodevelopmental disorders
  • Introduction
  • Development of the human cortex
  • Modeling human cortical interneuron development in vitro
  • The development of protocols for cortical interneurons from human pluripotent stem cells (hPSCs) to model neurodevelopmenta.
  • A protocol for cortical interneuron derivation from human pluripotent stem cells (hPSCs)
  • Equipment and supplies
  • Reagents
  • Preparation of reagents
  • Accutase cell detachment solution
  • B-27 supplement (50×) minus vitamin A
  • Preparing matrigel
  • Coating tissue culture plates with Matrigel
  • Coating tissue culture plates with Matrigel-Laminin
  • Small molecule preparation
  • Media composition
  • Protocol
  • Specification of cortical interneuron progenitors from hPSCs
  • Maintenance and expansion of cIN NPCs
  • Cryopreservation of cIN neural progenitor cells
  • Revival and maintenance of cryopreserved cIN neural progenitor cells
  • Interneuron differentiation and maturation from cIN neural progenitor cells
  • Enrichment and purification of cIN neural progenitor cells and neurons
  • Enrichment for post-mitotic cINs with neural rosette selection reagent
  • Purification of post-mitotic cINs with NCAM bead selection
  • Critical steps and troubleshooting
  • Cellular phenotyping of hPSC-derived cINs
  • Using immunocytochemistry to benchmark hPSC-derived cINs and to assess NDD-related alterations of neurodevelopment
  • Morphometric analysis of neurite extension and length
  • Neuronal migration assay
  • Measurement of synaptic puncta
  • Alternate protocol for derivation of cIN NPCs from hPSCs
  • Alternate protocol for differentiation of cIN NPCs into interneurons
  • Acknowledgments
  • References
  • 4
  • Development of transcription factor-based strategies for neuronal differentiation from pluripotent stem cells
  • Introduction
  • Neuron differentiation driven by transcription factors
  • Dopaminergic (DA) neurons
  • Glutamatergic neurons
  • GABAergic neurons
  • Cholinergic motor neurons
  • Retinal ganglion cells
  • Glia: astrocytes, oligodendrocytes, and microglia.
  • Transcription factor-driven differentiation: considerations when designing a new protocol
  • Design a cocktail of transcription factors
  • Transcription factor delivery
  • Genome integrating vectors
  • Non-genome integrating viral vectors
  • Synthetic mRNA
  • Summary and future directions
  • Acknowledgement
  • References
  • 5
  • Differentiation of Purkinje cells from pluripotent stem cells for disease phenotyping in vitro
  • Development of the cerebellum
  • Differentiation of pluripotent stem cells into Purkinje cells
  • Cerebellar organoids derived from iPSCs and ESCs in 3D cultures
  • Human iPSC- and ESC-derived Purkinje cell differentiation in 2D co-cultures with mouse cerebellar cells
  • Functional characterization of human pluripotent stem cell-derived Purkinje cells in vitro and in vivo
  • Challenges in the differentiation of human Purkinje cells in 2D- and 3D-cell cultures
  • Disease phenotyping of Purkinje cells
  • Purkinje cells in cerebellar ataxia
  • Mouse Purkinje cell models of cerebellar ataxia
  • Human iPSC-derived NPCs and Purkinje cells in cerebellar ataxia
  • Purkinje cells in Tuberous Sclerosis Complex (TSC)
  • Mouse Purkinje cell models of TSC
  • TSC patient iPSC-derived Purkinje cells
  • Future perspectives for stem cell-derived Purkinje cells in translational medicine
  • Cell transplantation for treatment of cerebellar degeneration
  • Drug screening with pluripotent stem cell-derived Purkinje cells
  • Acknowledgments
  • References
  • 6
  • Brain organoids: models of cell type diversity, connectivity, and disease phenotypes
  • Introduction
  • Cerebral organoids
  • Human corticogenesis overview
  • Organoid differentiation overview
  • Fidelity of hCO cell types and organization
  • Other brain region specific organoids
  • Neuronal activity and connectivity
  • Synaptic activity
  • Connectivity of neuronal organoids
  • Non-neuronal cells.
  • Astrocytes
  • Oligodendrocytes
  • Microglia
  • Vascularization/nutrient distribution
  • Summary of non-neuronal cells
  • Use of models in disease
  • Microcephaly modeling with hCOs
  • ASD modeling with hCOs
  • Molecularly defined ASD
  • Idiopathic ASD
  • Limitations of hCO modeling for CNS disorders
  • Reproducibility
  • Sources of variability in organoid model systems
  • Addressing reproducibility
  • Conclusions and future directions
  • References
  • II
  • The use of iPSC-derived neurons to study neurological disorders
  • 7
  • Human models as new tools for drug development and precision medicine
  • Introduction
  • Drug development pipeline
  • Human models as a screening tool for personalized precision medicine
  • Monolayer models
  • Organoids
  • Organ-on-chip platforms
  • Conclusion
  • References
  • 8
  • Use of cerebral organoids to model environmental and gene x environment interactions in the developing fetus an ...
  • Introduction
  • Maternal immune activation
  • Cerebral organoids as a model system to study MIA and neuroinflammation
  • Cerebral organoids as a model system to study infectious diseases that cause neurodevelopmental disorders
  • Zika virus
  • SARS-CoV-2
  • Human immunodeficiency virus (HIV)
  • Toxoplasmosis
  • Cytomegalovirus (CMV)
  • Herpes simplex virus (HSV)
  • Cerebral organoids and cellular stress
  • Heat shock
  • Fetal alcohol syndrome
  • Cerebral organoids to model neurodegenerative disorders
  • Alzheimer's disease (AD)
  • Cerebral organoids in familial AD
  • Modeling sporadic AD
  • Cerebral organoids for drug development in AD
  • Modeling Parkinson Disease using organoid cultures
  • Conclusion
  • References
  • 9
  • iPSC-derived models of autism: Tools for patient phenotyping and assay-based drug discovery
  • Introduction
  • Syndromic autisms
  • Fragile X syndrome
  • Rett syndrome
  • FOXG1 deletion syndrome
  • Tuberous sclerosis.
  • Pheland McDermid syndrome
  • Prader-Willi and Angelman syndromes
  • Timothy syndrome
  • iPSC studies to model ASDs in vitro
  • iPSC studies focused on syndromic and sporadic autisms
  • iPSC studies focusing on sporadic non-syndromic autism
  • Data collected by studies focused on iPSCs from idiopathic autism
  • Gene expression profiling
  • Concordances in gene expression profiles obtained from studies on iPSC-derived cells and post-mortem brain tissue from idio ...
  • Morphological and electrophysiological properties in iPSC-derived neurons from patients with idiopathic autism
  • Similar phenotypes between iPSC-derived neurons from patients with sporadic or syndromic autisms and idiopathic autism
  • 3D models of ASDs-a focus on organoids, spheroids, and assembloids
  • The use of iPSCs to develop assays and novel therapies that can be translated to the clinic for ASD
  • Limitations for using iPSC-derived neurons in drug screening platforms
  • Quality control testing
  • Automation challenges
  • Cost
  • Small "n"
  • Epigenetic memory
  • Well-to-well variability
  • Variability within cell lines
  • Variability across differentiation batches
  • Disease modeling
  • Screening of simple phenotypes
  • The use of iPSC-derived neurons for personalized medicine
  • Conclusions
  • References
  • 10
  • Probing the electrophysiological properties of patient-derived neurons across neurodevelopmental disorders
  • Induced pluripotent stem cells and modeling brain disorders
  • Progressing from gene discovery to functional gene groupings to pathophysiology
  • Neuronal networks represent a logical level for the manifestation of NDDs
  • Micro-electrode arrays as a scalable high-throughput functional assay
  • Phenotyping NDD patient-derived neurons using MEA recordings
  • Fragile X and Rett syndrome
  • Kleefstra syndrome
  • Neuronal networks as converging pathways?.